Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies-Reference-Cited by-同舟云学术

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies

Published:2007-06 Issue:3 Volume:10 Page:81-100
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Tortora Giampaolo,Bianco Roberto,Daniele Gennaro,Ciardiello Fortunato,McCubrey James A.,Ricciardi Maria Rosaria,Ciuffreda Ludovica,Cognetti Francesco,Tafuri Agostino,Milella Michele

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference199 articles.

1. Adjei, A.A., Cohen, R.B., Franklin, W.A., Molina, J., Hariharan, S., Temmer, E., Brown, S., Maloney, L., Morris, C., Eckhardt, S.G., 2006. Phase I Pharmacokinetic and Pharmacodynamic Study of the MEK Inhibitor AZD6244 (ARRY-142886). International Conference on Molecular Targets and Cancer Therapeutics, EORTC.

2. Intracellular signal transduction pathway proteins as targets for cancer therapy;Adjei;J. Clin. Oncol.,2005

3. A Phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC);Adjei;J. Clin. Oncol.,2005

4. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo;Alessi;J. Biol. Chem.,1995

5. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis;Aligayer;Cancer,2002

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interpreting drug synergy in breast cancer with deep learning using target-protein inhibition profiles;BioData Mining;2024-02-29

2. Personalized radiation therapy for glioblastoma;Chinese Clinical Oncology;2024-02

3. Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition;Pharmaceutics;2023-09-23

4. Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer;Molecular Oncology;2023-08-31

5. Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories;Biomolecules;2023-08-25